Gout Flares and Mortality After Sodium-Glucose Cotransporter-2 Inhibitor Treatment for Gout and Type 2 Diabetes
Main finding · Recurrent gout flaresResult — go to the resultRelative rate 0.79 95% CI 0.65–0.97Authors' conclusion
The findings of this cohort study suggest that SGLT2i were associated with a lower risk of recurrent gout flares and mortality than their active comparators in patients with gout and type 2 diabetes.
Study context
- Population
- Patients with gout and type 2 diabetes with GP visits, UK primary care database, January 1, 2013, to March 31, 20224,604 [77.6%] men
- Participants
- 5,931 patients
- Exposure
- SGLT2i vs active comparators
- SGLT2in = 1,548
- Active comparatorsn = 4,383reference
- Outcome
- Number of recurrent gout flares (recorded codes and prescription records)
Methodological detailspopulation-based, propensity score overlap weighting, Poisson regression or Cox proportional hazards model
- Population-based
- Propensity score overlap weighting
- Poisson regression or Cox proportional hazards model
Main finding
Recurrent gout flares
Relative rate
0.79
95% CI 0.65–0.97
As reported in the abstract
Observational data: associations, not effects.
Secondary outcomes
Per 1000 person-years
| Outcome | SGLT2i | Active comparators | Rate difference (per 1000 person-years) (95% CI) | |
|---|---|---|---|---|
| First recurrent gout flare | −8.8 (−17.2 to −0.4) | |||
| All-cause mortality | 18.8 | 24.9 | −6.1 (−10.6 to −1.6) | |
| −20−10010Difference, per 1000 person-years (linear scale) |
| Outcome | HR (95% CI) | |
|---|---|---|
| First recurrent gout flare | 0.81 (0.65–0.98) | |
| All-cause mortality | 0.71 (0.52–0.97) | |
| 0.512Hazard ratio (log scale) |
Original publication
Gout Flares and Mortality After Sodium-Glucose Cotransporter-2 Inhibitor Treatment for Gout and Type 2 Diabetes. JAMA Netw Open. Published 1 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →